Vincristine sulfate

目录号：S1241 别名： Leurocristine

Molecular Weight(MW): 923.04

Vincristine sulfate通过与微管蛋白结合而抑制微管聚合，IC50为32 μM。

规格

价格

库存

购买数量

10mg	RMB 582.05	现货
50mg	RMB 2229.59	现货
200mg	RMB 7118.45	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户购买Selleck的此次产品后发表的文献4篇：

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506

J Pharmacol Exp Ther, 2014, 350(3):646-56

PubMed: 24993360

Int J Mol Sci, 2012, 13(9):10736-49

PubMed: 23109819

Lipids Health Dis, 2016, 15:152

PubMed: 27613245

客户使用该产品的2个实验数据：

Plk inhibitor cooperates with chemotherapeutic agents. Conditional patched mutant tumor cells were treated with increasing concentrations of the chemotherapeutic agents vincristine alone or in combination with 10 nMol/L BI-2536. Cells were cultured for 48 hours, pulsed with 3H-Td, and harvested for analysis of 3H-Td incorporation at 66 hours.

Cancer Research, 2013, 73(20): 6310-22 . Vincristine sulfate purchased from Selleck.

for HXO-RB44 cells, IC50 values for VCR were changed in the different SG600 treatment groups. The results are representative of three independent experiments and of f our replicates in each experiment.

Int J Mol Sci 2012 13, 10736-10749 . Vincristine sulfate purchased from Selleck.

产品安全说明书

Microtubule Associated抑制剂选择性比较

生物活性

产品描述

Vincristine sulfate通过与微管蛋白结合而抑制微管聚合，IC50为32 μM。

靶点

Microtubules ^[1]
(Cell-free assay)

32 μM

体外研究

Vincristine抑制微管蛋白二聚体聚合亚单位,抑制它们的聚合作用，K_i为85 nM。^[1]在低浓度时，Vincristine抑制纺锤体，使染色体分离失败，进而导致中期停滞，并抑制有丝分裂。在较高浓度时，Vincristine可能干扰且诱导全部微管解聚。^[2] Vincristine 诱导肿瘤细胞凋亡，且抑制SH-SY5Y细胞增殖，IC50为0.1 µM。Vincristine诱导有丝分裂停滞，促进caspase-3和-9及cyclin B的表达，但降低cyclin D的表达。^[3] Vincristine通过干扰微管功能而诱导神经毒性形成，这会导致轴突运输堵塞，从而导致轴突变性。^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HepG2.2.15	NEDRVXNE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NF\aVHIxNTBwNTFOwG0>	Mk\KNlQhcA>?		Ml:z[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl?	MkHENlU3PjN5Nkm=
HepG2-HBV1.1	NYDBT2JnSXCxcITvd4l{KEG\|c3H5	NX7sPZVVOC1yLkWg{txO	NHHXS2gzPCCq		MVXpcoR2[2W\|IHHwc5B1d3OrczDkc5NmKGSncHXu[IVvfGy7	NFXJTGIzPTZ4M{e2PS=>
HepG2.2.15	NGnyWIVHfW6ldHnvckBCe3OjeR?=	M1zSO\|AvOSEQvF2=	MmOxNlQhcA>?		M2S4cpBzd22xdHXzJIhmeGG2aYTpd{BDKH[rcoXzJJBzd3SnaX6g[ZhxemW\|c3nvci=>	MY[yOVY3Ozd4OR?=
HepG2-HBV1.1	MkToSpVv[3Srb36gRZN{[Xl?	MmLtNE4yKM7:TR?=	M1vwNVI1KGh?		M174WpBzd22xdHXzJIhmeGG2aYTpd{BDKH[rcoXzJJBzd3SnaX6g[ZhxemW\|c3nvci=>	NHfwfWszPTZ4M{e2PS=>
HepG2-HBV1.1	M2riXWZ2dmO2aX;uJGF{e2G7	NXvIU29wOC5zIN88US=>	MlKwOFghcA>?		M1LrPJBzd22xdHXzJINmdGxiZYjjdoV1cW:wIH;mJIhmeGG2aYTpd{BDKH[rcoXzJI52[2ynb3PhdJNq\HNiaX7zeIVi\CCxZjDo[ZBifGm2aYOgRkB3cXK3czDEZY5mKHCjcoTpZ4xmew>?	MnryNlU3PjN5Nkm=
HepG2-HBV1.1	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWWwMlEh\|ryP	MW[xMVUh\A>?		MUXpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjD0bY1mKGSncHXu[IVvfGy7	NILFfYozPTZ4M{e2PS=>
HepG2-HBV1.1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWiwMlEh\|ryP	MlrJNU02KGR?		NV\qe5d[cW6qaXLpeJMhfGinIIDyc4xq\mW{YYTpc44hfGmvZTDk[ZBmdmSnboTsfS=>	NFXOW4czPTZ4M{e2PS=>
HepG2-HBV1.1	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NYnlVFNJOC5zIN88US=>	NFf3cWsyOi15MjDo		NIi4OHZqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0JIF1KFNvcHjhd4U>	NVXSbHN{OjV4NkO3Olk>
HepG2-HBV1.1	M1vrSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYizV4J7OC5zIN88US=>	MXOxNk04OiCq		M2Wweolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4SgZZQhWy2yaHHz[S=>	M3LXTlI2PjZ\|N{[5
Raji	MVzGeY5kfGmxbjDBd5NigQ>?	M{\vVlAvPcLizszN	MnLUO\|IhcA>?		MX3hZo9tcXOqZYOgZZV1d3CqYXf5xsA>	M37EPVI2PDR4M{e3
SK-MEL-28	MlLjSpVv[3Srb36gRZN{[Xl?	M37CTFMxKG6P	MXu2JIg>		MlXybY5lfWOnczDHNwKBm01iY3XscE1kgWOuZTDhdpJme3R?	NV2xS4E{OjV\|MUOwNVA>
H157	NXWxb4dCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIrTRXJKSzVyPUGuNFMhyrFiMD6wOEBucXV{TR?=	MWmyOVI2PzlzMR?=
Jurkat	M{T6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NYT6NmhyOS1\|IH7N	M4ixXlQ5yqCq	M{WyOWROW09?	MlTZ[IVkemWjc3XzJJZq[WKuZTDj[YxtKG63bXLldpMh\G:\|ZTDk[ZBmdmSnboTsfS=>	NHXETJAzPTF3NkG0Oi=>
CEM	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MnvvNU0{KG6P	MYK0POKhcA>?	MlO1SG1UVw>?	M4nkN4Rm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk>	NGTmNm4zPTF3NkG0Oi=>
P12	MmDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGHCOI8yNTNibl2=	M4LGSVQ5yqCq	NGf5THNFVVOR	M2rDUoRm[3KnYYPld{B3cWGkbHWgZ4VtdCCwdX3i[ZJ{KGSxc3Wg[IVx\W6mZX70cJk>	NEDwcHkzPTF3NkG0Oi=>
KB	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXfJR\|UxRTBwMEC0PUDDuSByLkCwNFEh\|ryP	MXiyOVA2QDV{Nh?=
KBv200 (ABCB1)	M1u2VWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm\yTWM2OD1yLkO0OlIhyrFiMD6wNFY3KM7:TR?=	NEPhRZgzPTB3OEWyOi=>
SUDHL6	NHniVXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEmx[5My6oDLzszN	M4XVUlQ5Nzd{IHi=		M4\vRYlvcGmkaYTzJINmdGxidnnhZoltcXS7IIPp[45q\mmlYX70cJk>	M4Xr[FI1QTZzNkC0
SUDHL6	NELWcXZHfW6ldHnvckBCe3OjeR?=	MXex5qCK\|ryP	MYq3NkBp		M3\MVYlv\HWlZYOgd4lodmmoaXPhcpQh[XCxcITveIlkKG2xcoDoc4xw\3liY3jhcodmeyClb4Ty[ZN1\WRid3n0bEBDS0xzMVGgd4lTVkF?	NU\wfoUxOjR7NkG2NFQ>
HCT-116	NIjCbZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVnke5dkT0l3ME21JI5O	MYWyOFkzPzh3Nx?=
SKNBe2C	NF;WVWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\QbmxKSzVyPUOyMljDuTRwMDDuUS=>	NEn4UY4zPDl{MUmyNC=>
IGNR91	NF71OnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGftN4JKSzVyPUK0MlPDuTFwNzDuUS=>	MYOyOFkzOTl{MB?=
SKNAS	MmPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYDJR\|UxRTFwNdMxNE4zKG6P	NEnETmIzPDl{MUmyNC=>
LAN1	MmfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2PQTGlEPTB;Mj6zxtExNjJibl2=	NYPEc21xOjR7MkG5NlA>
SHSY5Y	Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVzJR\|UxRThwMtMxNE43KG6P	MlnrNlQ6OjF7MkC=
A549-WT	NF6yOFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4O0XWlEPTB;MUmuOFM4KMLzIECuOVk1KCCwTR?=	NUXiO49UOjR6NUi4Nlc>
A549-R	MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3judWlEPTB;MUKuNVc5KMLzIECuN\|M{KCCwTR?=	Mn3QNlQ5PTh6Mke=
MCF-7-WT	NXy4RWVDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfOfFBKSzVyPUG3Mlc2OiEEsTCwMlIyQCBibl2=	MVGyOFg2QDh{Nx?=
MCF-7-R	NXHwSoxxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2rPN2lEPTB;NT61N\|khyrFiMD6xOFQhKG6P	NV\wco9WOjR6NUi4Nlc>
A549-R	M{[wZmN6fG:2b4jpZ4l1gSCDc4PhfS=>				NWrV[ZB4UUN3ME2xNk4yPzhiwsGgNE4{OzNibl2=	NHLN[\|QzPDh3OEiyOy=>
MCF-7-R	NF3uTWJEgXSxdH;4bYNqfHliQYPzZZk>				M2f3Z2lEPTB;NT61N\|khyrFiMD6xOFQhdk1?	M3rvWVI1QDV6OEK3
SW620	NIrJc2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoP0TWM2OD15LkiwJOKyKDBwMEigcm0>	Mn2xNlQ4OjZ5M{m=
SW620/AD300	M1TWVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWHWOplEUUN3ME25NFkvPjBiwsGgPE46OSCwTR?=	M3G2[FI1PzJ4N{O5
HEK293/pcDNA3.1	M4LEfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVnKNmFMUUN3ME2xMlQ2KMLzIECuNlAhdk1?	MnLNNlQ4OjZ5M{m=
HEK293/ABCC1	NUC4[\|BTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYDa[5lSUUN3ME2xPU4zQSEEsTCyMlA5KG6P	MmTxNlQ4OjZ5M{m=
TCC	M1LBPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M2rY[FI1KGh?		NFXWTnFKSzVyPUewJI5O	NETJVXUzPDdzNkm0OC=>
TCC	MoTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M3nD[lQ5KGh?		M3zVXGlEPTB;NUCgcm0>	MoP4NlQ4OTZ7NES=
HepG2/ADM	NFjnZ2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M120[2lEPTB;Mj63PFY{yrFyLkKzO\|Eh\|ryP	NX7j[mt7OjR5MES1OVY>
HepG2	NGLYTm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXuToV7UUN3ME2wMlAyOTYEsUCuNFAyPyEQvF2=	NXTYZ2l2OjR5MES1OVY>
MCF-7/ADR	MofmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\tTWM2OD12LkS4NlbDuTBwMkC3NEDPxE1?	MVmyOFcxPDV3Nh?=
MCF-7	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYjWbJptUUN3ME2wMlAyPToEsUCuNFA3OiEQvF2=	NFHPdXQzPDdyNEW1Oi=>
A-172	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MXGwMlHDqM7:TR?=	NX;QT45HOjRxN{KgbC=>		MXrpcohq[mm2czDj[YxtKGe{b4f0bEB1cW2nIHTldIVv\GWwdHz5	NX;QNZNWOjR3M{CyN\|U>
U-251MG	M1HqRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MojjNE4yyqEQvF2=	Ml3mNlQwPzJiaB?=		MnnUbY5pcWKrdIOgZ4VtdCCpcn;3eIghfGmvZTDk[ZBmdmSnboTsfS=>	Mlv5NlQ2OzB{M{W=
DLD-1	MXjGeY5kfGmxbjDBd5NigQ>?	MofrNVAxKG6P	Ml7nOFghcA>?		NYj2flRmeHKxbX;0[ZMhWlWQWEOg[IVu\XSqeXzheIlwdsLi	M37BTFI1PDB\|NEWz
CCD18Co	MXnGeY5kfGmxbjDBd5NigQ>?	M3;ZO\|ExOCCwTR?=	M4fhWlQ5KGh?		NIftT3pxem:vb4Tld{BTXU6[MzDk[Y1mfGi7bHH0bY9vyqB?	NF7kUIgzPDRyM{S1Ny=>
DLD-1	M{\QXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M4HvXlAuOTByMDDuUS=>	MVG0PEBp		NEPsPGRqdmirYnn0d{Bk\WyuIHfyc5d1cCCmb4PlJIRmeGWwZHXueIx6	NEfxRXYzPDRyM{S1Ny=>
CCD18Co	NHTYbm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MofrNE0yODByIH7N	MUS0PEBp		NUPjcnM{cW6qaXLpeJMh[2WubDDndo94fGhiZH;z[UBl\XCnbnTlcpRtgQ>?	NXOxV5lkOjR2MEO0OVM>
HepG2	NUfKSGVPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NUfPVllVOjRiaB?=		MYHJR\|UxRTV{LkZihKnPxE1?	MUOyOFM1OTZ6OB?=
HEK293/pcDNA3.1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTBwMEC0xtExNjByMEOg{txO	NETybI8zPDJ6NEe4Ny=>
HEK293/MRP1	MnPoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnNOYJ6UUN3ME2wMlA2PcLzMD6wNVIxKM7:TR?=	NEWzZZEzPDJ6NEe4Ny=>
Ramos	NHz3OlhCeG:ydH;zbZMhSXO\|YYm=	MXmy5qCK\|ryP	MVi0PEBp		M32xTIlv\HWlZYOgN\|QvPiYEsUGuPVImKGGyb4D0c5Nqew>?	MofJNlQzPTZ2OUG=
NCI-H1299/pcDNA3	NIPUUJBE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NGXocYgxNTJyIH7N	NHvpTVI6PiCq		MkS1bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	M4PXOFI1OTd5MEGy
H1299/ICAM-3	MYTD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MkC4NE0zOCCwTR?=	MVG5OkBp		MlTGbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>?	NFyxNoEzPDF5N{CxNi=>
NCI-H1299/pcDNA3	M1zLVWZ2dmO2aX;uJGF{e2G7	MofZNU82NzFyL{KwxsBvVQ>?	MkC0PVYhcA>?		NGSyT\|BqdmS3Y3XzJINt\WG4YXflJI9nKGOjc4Dhd4V{NTNuIEisJFktKGGwZDDQRXJR	NXzvT2xsOjRzN{ewNVI>
H1299/ICAM-3	NF;TPZBHfW6ldHnvckBCe3OjeR?=	NVnS[Y1vOS93L{GwM\|IxyqCwTR?=	NULKRWJ{QTZiaB?=		Mn\5bY5lfWOnczDjcIVifmGpZTDv[kBk[XOyYYPld{0{NCB6LDC5MEBidmRiUFHSVC=>	M4jkfVI1OTd5MEGy
W1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHu5NZJKSzVyPUCuNFA{OiEQvF2=	NEPye3YzPDF2MEG3Oi=>
W1VR	NXLkS4RHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVnJR\|UxRTBwMEW2JO69VQ>?	NW\zUIJ[OjRzNECxO\|Y>
K562	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkDwTWM2OD1yLkCzNkDDuSByLkCwNUAh\|ryP	NH3XZ3AzPDF\|NUmzOy=>
K562/ADR	NH7IWYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rifWlEPTB;Mz6yOlEhyrFiMD60NVIh\|ryP	NEPTfI8zPDF\|NUmzOy=>
K562	M13LdmFxd3C2b4Ppd{BCe3OjeR?=	NEjYfVMxNjNizszN	NEPCeY0zPCCq		NUXnb29pcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?=	MX[yOFE{PTl\|Nx?=
K562/ADR	NWfBW\|Q{SXCxcITvd4l{KEG\|c3H5	MYezJO69VQ>?	NHKwcFAzPCCq		NED3NFdqdmS3Y3XzJIFxd3C2b4Ppdy=>	NY\BNIc{OjRzM{W5N\|c>
A549	MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTBwMUCgxtEhOC5yMzFOwG0>	M{iwOFI{QTdzMEe1
K562	M4TkemNmdGxiVnnhZoltcXS7IFHzd4F6	Mn\oN{44PeLCk{[wxsBvVQ>?	Ml;oO\|LDqGkEoB?=		NVrwbXBocW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?=	NVzweHpPOjN6N{eyNlM>
lucena	NH7OZWdE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NEDzRWk{Njd34pETOlDDqG6P	M4XD[VczyqCqwrC=		NFzuR\|dvdyCnZn\lZ5Q>	MUKyN\|g4PzJ{Mx?=
FEPS	MkPDR4VtdCCYaXHibYxqfHliQYPzZZk>	NWXyeZc4Oy55NfMAl\|YxyqCwTR?=	M4LnWFczyqCqwrC=		M1;tSY5wKGWoZnXjeC=>	MkHLNlM5Pzd{MkO=
A2780	NVL1cI1kT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWezXXV[UUN3ME2zMlUhdU1?	NEDJOY0zOzh{OUKwNy=>
ACHN	M163T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLFVI1KSzVyPECuNUBuVQ>?	MX:yN\|gzQTJyMx?=
U-937	MmD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M33S[2lEPTB:M{Sgcm0>	M3;3b\|I{QDJ7MkCz
Jurkat	NI\Kd2xCeG:ydH;zbZMhSXO\|YYm=	MX[1xsDPxGdxbX\|CpC=>	NILpdVkzPCCq		M3TJSYlv\HWlZYOgZZBweHSxc3nzJJNq\26rZnnjZY51dHl?	NUn1N2NoOjN6MUC0NFk>
Jurkat	M1rFdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWO1xsDPxGdxbX\|CpC=>	NITQNlIzPCCq		Ml3ZZZJz\XO2IFr1dotifCClZXzsd{BqdiCJMj;NJJBp[XOn	NUC5[3J3OjN6MUC0NFk>
Hep-2	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmH1TWM2OD1yLkC0xtExNjBzIN88US=>	M4KzbVI{PzhyNEK0
Hep-2/v	NGiwVZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1yyZmlEPTB;MT64xtExNjJyIN88US=>	M17HO\|I{PzhyNEK0
SGC-7901	Ml;KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NIOxO2kxNTFyIN88[{9udA>?	NU\RZZJtOjRxNEivO\|IhcA>?		NHnNVmZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDkc5NmKGGwZDD0bY1mKGSncHXu[IVvfCCvYX7u[ZI>	MWKyN\|c1OzV5Mh?=
SGC-7901/VCR	M{P1Wmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NULN[XJtOC1zMDFOwIcwdWx?	MnzRNlQwPDhxN{KgbC=>		MUHpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCmb4PlJIFv\CC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	NEXVUlEzOzd2M{W3Ni=>
SGC-7901	M4fnPGFxd3C2b4Ppd{BCe3OjeR?=				NYCzOHlXcW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?=	NEL4ZVIzOzd2M{W3Ni=>
SGC-7901/VCR	Mm\YRZBweHSxc3nzJGF{e2G7				NHjLXIJqdmS3Y3XzJIFxd3C2b4Ppd{B{cWewaX\pZ4FvfGy7	M17kXlI{PzR\|NUey
KB-3-1	M4K3V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\EWGlEPTB;MT62OkDDuSByLkG2NkDPxE1?	MYmyN\|Y4OzR2NR?=
KB-C2	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIXMT5JKSzVyPUKwNk42PiEEsTC0Nk41QDFizszN	NHyw[IozOzZ5M{S0OS=>
KB-3-1	NX;2b\|B5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PyNmlEPTB;MT6yOkDDuSByLkCyO{DPxE1?	M3vpXVI{Pjd\|NES1
KB-V1	MkS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXzyc3llUUN3ME2yNFgvQDViwsGgNlAvPCEQvF2=	NUn1UYgzOjN4N{O0OFU>
HEK293/pcDNA3.1	M1n3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEW2cYZKSzVyPUK0MlEhyrFiMD6yNFQh\|ryP	MUKyN\|Y4OzR2NR?=
HEK293/ABCB1	NEPyZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHkTWtHUUN3ME2zOVEzNjhiwsGgN\|c5NjN7MTFOwG0>	M2rXSVI{Pjd\|NES1
A549/EGFP	MlfkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3nMd\|AvODFvMUCwNEDPxE1?			M2fvNmlEPTB;OE[uO{DDuSB{OT6xJO69VQ>?	MlntNlM3OzR{OEK=
A549/Slug	NGDnbnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NUT0WWVUOC5yMT2xNFAxKM7:TR?=			NVvmS3ZLUUN3ME25MlchyrFiMz6xJO69VQ>?	MXiyN\|Y{PDJ6Mh?=
JFCR39	NHW1dlFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NHz6T4YyKML3TR?=	MnrSNlQhcA>?	NYfmcpp3TE2VTx?=	MXztZZJs\WSueTDpcoNz\WG\|ZYOgeIhmKG63bXLldkBw\iCJMj;NJJBp[XOnIHPlcIx{	NUW4OJZqOjN3OUiyO\|Y>
A549	NVfYRmIxTnWwY4Tpc44hSXO\|YYm=	NEDQOGUyODBibl2=	MmrPNVYhcA>?	NFvhXHFFVVOR	NX3NOZk5dGWjZIOgeI8h[SCub4PzJI9nKG2rY4LveJVjfWyncx?=	MUCyN\|U6QDJ5Nh?=
SGC7901	Mor6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3zmNGlEPTB;MT6yOwKBkcLz4pEJNE4yOSEQvHevcYw>	NUfjOYoyOjN3NkS0PFI>
SGC7901/LV-NC	NEDINmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm\FTWM2OD1zLke35qCKyrIkgJmwMlE3KM7:Zz;tcC=>	MUiyN\|U3PDR6Mh?=
SGC7901/LV-SGO1	NE\BTlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkLjTWM2OD12LkO25qCKyrIkgJmwMlM4KM7:Zz;tcC=>	MlyyNlM2PjR2OEK=
SGC7901/VCR	M2T1eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkL0TWM2Oz1{MD61N-KBkcLz4pEJNU46PiEQvHevcYw>	NIHJVpMzOzV4NES4Ni=>
SGC7901/VCR-NC	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIfhSI9KSzVyPUG5Mlg36oDLwsJihKkzNjBzIN88[{9udA>?	MYCyN\|U3PDR6Mh?=
SGC7901/VCR-si-SGO1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkfmTWM2OD14LkG45qCKyrIkgJmxMlA{KM7:Zz;tcC=>	MkXNNlM2PjR2OEK=
SGC7901/ADR	NIH6VWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnq1TWM2OD15Lki15qCKyrIkgJmwMlY1KM7:Zz;tcC=>	Ml30NlM2PjR2OEK=
SGC7901/ADR-NC	MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFvRWYtKSzVyPUiuPVPjiIoEsfMAjVAvPjhizsznM41t	MWmyN\|U3PDR6Mh?=
SGC7901/ADR-si-SGO1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MonSTWM2OD1\|LkS25qCKyrIkgJmwMlI6KM7:Zz;tcC=>	MYSyN\|U3PDR6Mh?=
SH-SY5Y	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUC3[2tROC5yMEGtNVAh\|ryP	M2[zb\|I1KGh?		MVTJR\|UxRTBwMUGzxtExNjBzMjFOwG0>	MV:yN\|EzQTB4NR?=
SH-SY5Y	NGnLc3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnLNNE4xODFvMUCg{txO	NIDZPFM1QCCq		Ml3tTWM2OD1yLkC3POKyOC5yMEmg{txO	M3ywVlI{OTJ7ME[1
SH-SY5Y	M{f3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlHTNE4xODFvMUCg{txO	NWLYd3pmPzJiaB?=		Mo\0TWM2OD1yLkC1NeKyOC5yMEig{txO	MX:yN\|EzQTB4NR?=
SH-SY5Y	MnXpRZBweHSxc3nzJGF{e2G7	NY\2bWRkOC5zIN88US=>	NGj2O4oxNTJ2IHi=		NV;3eoNGcW6mdXPld{BieG:ydH;zbZMhd2ZiU1itV3k2YSClZXzsd{Bnd2yub4fpcoch[2WubDDjfYNt\SCjcoLld5Qh[XRidHjlJGczN01icHjhd4U>	MX[yN\|EzQTB4NR?=
SH-SY5Y	NIrB[2tCeG:ydH;zbZMhSXO\|YYm=	M3zpcVAvOSEQvF2=	M4H5TlAuOjRiaB?=		MWPpcoR2[2W\|IH3peI91cWNiYYLy[ZN1yqB?	NIDoNIIzOzF{OUC2OS=>

... Click to View More Cell Line Experimental Data

体内研究

Vincristine 按3 mg/kg剂量单独腹腔注射给药携带双侧皮下移植瘤RH12或RH18的小鼠，平均生长延迟120天和52天以上，且再植指数分别为0.06％和5％。^[5] Vincristine 处理小鼠，通过宿主细胞介导的血管效应及直接的微管蛋白介导的的细胞毒性作用而对皮下结肠38肿瘤起作用。Vincristine (5 mg/kg) 降低肿瘤血流量，降低近75%。^[6]

细胞实验：^[1]	+ 展开 Cell lines: B16 黑色素瘤细胞 Concentrations: 10 nM Incubation Time: 3 天 Method: 细胞按5 × 10⁴ cells/mL的浓度接种在含2 mL培养基的35-mm 实验板上，在37°C下含5% CO₂ 和95% 空气的环境下生长24小时。然后使用有或无10 nM药物的新鲜培养基更换原来的培养基，继续增殖3天。使用胰蛋白酶和EDTA将细胞分离后，每天使用库氏计数器完成细胞计数 (Only for Reference)
动物实验：^[5]	+ 展开 Animal Models: 携带人类横纹肌肉瘤移植瘤Rh12的鼠 Formulation: 水溶液 Dosages: 3 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

+ 展开

溶解度 (25°C)

体外	DMSO	100 mg/mL (108.33 mM)
	Water	60 mg/mL (65.0 mM)
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： Saline	30 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Vincristine sulfate SDF

分子量	923.04
化学式	C₄₆H₅₈N₄O₁₄S
CAS号	2068-78-2
稳定性	3 years -20°C powder
稳定性	2 years -80°C in solvent
别名	Leurocristine

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2018-11-16)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03571321	Not yet recruiting	Acute Lymphoblastic Leukemia\|ALL Childhood\|ALL	University of Chicago\|Incyte Corporation	September 5 2019	Phase 1
NCT03349281	Recruiting	Refractory Acute Lymphoblastic Leukemia\|Relapsed Acute Lymphoblastic Leukemia	Julio Barredo\|Takeda\|University of Miami	March 2019	Phase 1
NCT03710772	Not yet recruiting	CD20 Positive\|Mantle Cell Lymphoma	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	January 31 2019	Phase 2
NCT03613428	Not yet recruiting	Acute T Cell Leukemia	Sichuan University	December 1 2018	Phase 1\|Phase 2
NCT03742258	Not yet recruiting	Diffuse Large B-Cell Lymphoma\|Diffuse Large B-Cell Lymphoma Activated B-Cell Type\|Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type\|Diffuse Large B-Cell Lymphoma Not Otherwise Specified\|High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements\|High Grade B-Cell Lymphoma Not Otherwise Specified\|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma	Northwestern University\|National Cancer Institute (NCI)	December 29 2018	Phase 1
NCT03704714	Not yet recruiting	Aggressive Non-Hodgkin Lymphoma\|B-Cell Non-Hodgkin Lymphoma\|CD20 Positive\|Diffuse Large B-Cell Lymphoma Unclassifiable\|Intravascular Large B-Cell Lymphoma\|Primary Mediastinal (Thymic) Large B-Cell Lymphoma\|T-Cell/Histiocyte-Rich Large B-Cell Lymphoma\|Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma	Northwestern University\|Bristol-Myers Squibb (BMS)\|National Cancer Institute (NCI)	November 8 2018	Phase 1\|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
I want to use the product #S1421 for mouse in vivo, could you please give us your advice about administration method?
回答：
According to the reference cited on our website, we test the solubility of S1421 Staurosporine in 4% DMSO/saline, and it is a suspension at 5 mg/mL. The compound can also be dissolved in the vehicle 4% DMSO/30% PEG 300/10% Tween 80/saline at 5 mg/ml as a clear solution for injection.

研究领域

产品类型

Vincristine sulfate

客户购买Selleck的此次产品后发表的文献4篇：

客户使用该产品的2个实验数据：

产品安全说明书

Microtubule Associated抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Vincristine sulfate SDF

计算器

摩尔浓度计算器

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2018-11-16)

技术支持

常见问题及建议解决方法

Microtubule Associated Signaling Pathway Map

相关Microtubule Associated产品